Ocugen (OCGN) announced that the European Commission, EC, has provided a positive opinion from the European Medicines Agency’s, EMA, Committee for Advanced Therapies, CAT, for OCU410 and OCU410ST Advanced Therapy Medicinal Product, ATMP, classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy-an advanced stage of dry age-related macular degeneration-and OCU410ST is being developed for Stargardt disease due to ABCA4-related retinopathies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Options Volatility and Implied Earnings Moves This Week, March 03 – March 06, 2025
- Ocugen Inc (OCGN) Q4 Earnings Cheat Sheet
- Ocugen reports FDA alignment on Phase 2/3 OCU410ST trial in Stargardt disease
- Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential
- Ocugen price target raised to $8 from $7 at H.C. Wainwright